Orforglipron Research Guide: Oral GLP-1 Receptor Agonist
Research overview of Orforglipron, Eli Lilly’s oral small-molecule GLP-1 receptor agonist studied for obesity and type 2 diabetes. Phase 3 data published in NEJM 2026. For laboratory research use only.
